Organisation paid for research Program year 2023 Source: CMS Open Payments

Advanced Research Associates LLC

Neither a doctor nor a teaching hospital

Research payments

$493,318

70 payments

Through program year 2023, Advanced Research Associates LLC is reported as receiving $493,318 in research payments, across 70 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$51,526	17
2022	Research	$441,196	50
2020	Research	$34	1
2019	Research	$562	2

Breakdown

Who paid Research payments · program years 2019–2023

AbbVie, Inc. $492,461 66 payments
Ucb SA $669 3 payments
UCB Biosciences Inc. $188 1 payment

Studies the money was for Research payments · program years 2019–2023

Hyperfunctional facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. BOTOX (onabotulinumtoxinA) was first approved for aesthetic treatment of glabellar lines in 2001 and is one of the most common nonsurgical procedures in aesthetic medicine. This is a proof-of-concept study to evaluate how safe this new OnabotA X formulation. $175,642 4 payments
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence $144,478 25 payments
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines $85,614 10 payments
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence $50,472 14 payments
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy $23,821 11 payments
The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence. $12,434 2 payments
A Phase 3, Multicenter, Randomized, Double-Blind Study With A 24-Week Active-Controlled Initial Treatment Period Followed By A 32-Week, Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $373 1 payment
A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $295 2 payments
A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $188 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.